Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine Tumors
NCT02786303 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2016-06-01
Summary
The diagnosis and the follow-up of neuroendocrine tumors can be difficult to assess, especially in the detection of metastasis as they can grow in different organs such as liver, lungs, bones or lymph nodes. Nowadays, the diagnosis is made with two main imaging techniques which are the thoraco-abdomino-pelvic CT-scan and a scintigraphic method (Octreoscan and sometimes a TEP-scan). The use of a whole-body MRI is more and more often used for the detection and evaluation of tumors and metastases; therefore, it could be used for neuroendocrine tumors. The MRI would allow to replace the two imaging techniques and to avoid the use of irradiation but also to have a better detection of metastases. This purpose of the study was to evaluate this statement by assessing the consistency between the routine techniques and the MRI and finally to update the recommendation if the study is positive.
Conditions
- Neuroendocrine Tumors With Metastasis
Interventions
- DEVICE
-
Whole-body diffusion- weighted MRI
Sponsors & Collaborators
-
CHU de Reims
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-30
- Primary Completion
- 2016-04-30
- Completion
- 2017-04-30
More Related Trials
-
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
NCT02966574 ·Status: UNKNOWN ·Phase: NA
-
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
NCT06842303 ·Status: RECRUITING ·Phase: NA
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
NCT01673906 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
NCT00842790 ·Status: COMPLETED
-
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
NCT04272658 ·Status: RECRUITING
-
Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases
NCT02316431 ·Status: COMPLETED
-
Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia
NCT04045834 ·Status: UNKNOWN
-
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
NCT03271281 ·Status: COMPLETED ·Phase: PHASE2
-
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT06795113 ·Status: RECRUITING
-
Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
NCT03353090 ·Status: COMPLETED
-
SPECT/CT in Endocrine and Neuroendocrine Tumors
NCT00230139 ·Status: COMPLETED ·Phase: NA
-
Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)
NCT02876731 ·Status: COMPLETED ·Phase: NA
-
Integrated PET/MR Imaging With Amino Acid Radiotracers in the Evaluation of Brain Neoplasms: Assessing Diagnostic Accuracy and Therapeutic Response
NCT07211360 ·Status: NOT_YET_RECRUITING
-
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775 ·Status: RECRUITING
-
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
NCT02134639 ·Status: COMPLETED
-
Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
NCT02646644 ·Status: COMPLETED
-
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537 ·Status: COMPLETED ·Phase: PHASE2
-
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
NCT04510311 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Detection and Characterization of Residual Masses in Lymphomas
NCT02300402 ·Status: COMPLETED
-
Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor
NCT04154241 ·Status: UNKNOWN ·Phase: NA
-
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT01747096 ·Status: COMPLETED ·Phase: NA
-
Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
NCT06773624 ·Status: RECRUITING ·Phase: NA
-
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
NCT01373736 ·Status: UNKNOWN ·Phase: PHASE3